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Abstract
Background: In England and Wales where less than 1% of the population are Injecting drug users
(IDUs), 97% of HCV reports are attributed to injecting drug use. As over 60% of the IDU
population will have been imprisoned by the age of 30 years, prison may provide a good location
in which to offer HCV screening and treatment. The aim of this work is to examine the cost
effectiveness of a number of alternative HCV case-finding strategies on prison reception
Methods: A decision analysis model embedded in a model of the flow of IDUs through prison was
used to estimate the cost effectiveness of a number of alternative case-finding strategies. The model
estimates the average cost of identifying a new case of HCV from the perspective of the health care
provider and how these estimates may evolve over time.
Results: The results suggest that administering verbal screening for a past positive HCV test and
for ever having engaged in illicit drug use prior to the administering of ELISA and PCR tests can
have a significant impact on the cost effectiveness of HCV case-finding strategies on prison
reception; the discounted cost in 2017 being £2,102 per new HCV case detected compared to
£3,107 when no verbal screening is employed.
Conclusion: The work here demonstrates the importance of targeting those individuals that have
ever engaged in illicit drug use for HCV testing in prisons, these individuals can then be targeted
for future intervention measures such as treatment or monitored to prevent future transmission.
Background
Hepatitis C (HCV) is a blood-borne viral infection that
affects the liver the causative agent of which was identified
only in 1989[1]. The virus is spread when blood from an
infected person gets into the bloodstream of another. In
the UK blood donations have been screened for HCV
since September 1991. Consequently, it is now very diffi-
cult to acquire HCV infection by blood transfusion.
Unlike many other blood borne viruses, sexual transmis-
sion is thought to be relatively rare[2]. HCV is an impor-
tant problem in current and previous injecting drug users
(IDU)s who are exposed to the virus through the sharing
of needles and injecting paraphernalia[3]. It has been
shown that the prevalence of HCV infection in current
and former IDUs in England and Wales is approximately
41%[4]. Co-infection of blood-borne viruses is also a
problem for IDUs, it has been found for IDUs in England
and Wales in 2000–2003 that approximately 30% of cur-
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rent IDUs were co-infected with HBV and HCV, and
approximately 1% were co-infected with HCV and
HIV[4].
In the EU, data from 63 data sources obtained covering
the period 1996–2002 in 14 countries of the EU were
available (no data was available from Sweden)[5]. The
HCV prevalence in IDUs was found to be as low as 35.7%
in the UK and as high as 80.6% in Denmark with the
mean across 14 European Union countries being 65.1%.
While an alternative study[6] that reviewed literature from
studies in the European Union from 1990–2000 found
that the incidence rates for HCV in the IDU population
ranged from 6.2 to 39.3 per 100 person years.
Using data on the number of deaths due to opiate over-
dose it has been estimated that the prevalence of opiate
users/injecting drug users has increased from less than
20,000 in 1980 to between 100,000 and 150,000 in 2000
in England and Wales[7]. Alternative estimates of the
prevalence of problematic drug use in the UK undertaken
in 2001 have ranged from 161,000–266,000[8].
Due to the illegality of injecting drug use and the close
association between crime and drug manufacture, traffick-
ing, supply, and use, those involved with injecting illicit
drugs frequently pass through the penal system[9]. This
suggests that prison is a good location to administer inter-
vention measures targeting the IDU population.
It was found in a previous unlinked anonymous surveil-
lance survey[4] that 49% of IDUs self reported that they
were unaware of their HCV infection while an alternative
study[10] found that in IDUs that tested positive for HCV
only 23% of them were aware of their positive status. This
lack of awareness of their infection status imposes a con-
siderable barrier to treatment and transmission preven-
tion.
There are a variety of alternative intervention measures
that target illicit drug use[11]; Prevention programmes
aim at the reduction of initiation or progress from experi-
mental to regular drug use, treatment programmes aim to
reduce drug use in experienced users, enforcement pro-
grammes aim at reducing the supply of drugs by targeting
traffickers or dealers for arrest and reducing the demand
for drugs by targeting the buyers of drugs, while harm
reduction programmes seek explicitly to reduce the
adverse consequences of drug use.
The work here considers the cost effectiveness of a range
of alternative HCV case-finding scenarios implemented
on reception into prisons in England and Wales to iden-
tify persons infected by chronic HCV (HCV RNA positive).
Each scenario will be compared by considering the cumu-
lative cost of identifying a new case of HCV (HCV RNA
positive) and how this cost changes over time as previ-
ously tested individuals return to prison. Incremental
cost-effectiveness analysis will also be undertaken.
Methods
Model structure
The model here is adapted from the model of the HBV
vaccination programme in prisons. This model describes
the flow of individuals through prison including the risk
of incarceration for IDUs and non-IDUs and is stratified
by injecting status and age[12]. The current IDU popula-
tion described here has been subdivided into new initiates
to injecting and experienced IDUs. New initiates to inject-
ing are defined as those IDUs with an injecting career
length of less than a year, and experienced IDUs are those
individuals with an injecting career length of greater than
one year. The force of infection estimates; defined as the
per capita rate that susceptibles acquire infection, for both
new initiates and experienced IDUs are taken from a pre-
vious study[13]. It is assumed that the force of infection
rates are constant over time and independent of prison
status. While it is acknowledged that the risk of blood-
borne virus infection amongst IDUs inside prison may be
significantly higher than in the community[14], obtain-
ing reliable force of infection estimates that distinguish
between prison status have not been obtained. Due to the
small proportion of HCV infections that have an identi-
fied risk factor other than injecting drug use in England
and Wales[15], it is anticipated that the force of infection
in non-IDUs will be extremely low, and so for this reason
it is assumed that only IDUs can become infected by HCV
with the incidence of new infections in the general popu-
lation (non-IDUs) assumed to be zero. For those persons
that are infected by HCV it is assumed at the time of infec-
tion that 80%[2] become HCV RNA positive, although
this assumption will be tested during sensitivity analysis.
HCV case-finding coverage
Currently there is no significant ongoing HCV case-find-
ing on reception into prisons across England and Wales. It
is assumed therefore that HCV case-finding coverage on
prison reception is expanded over time to reflect the roll-
ing out of an HCV case-finding programme across prisons
in England and Wales (1). shows the percentage of prison
receptions in England and Wales where case-finding is
undertaken over time assumed in this analysis.
Case-finding pathway on prison reception
The case-finding pathway through prison reception pro-
posed here is taken directly from a previous study using
publicly available information describing the implemen-
tation of screening and treatment of HCV in the Isle of
Wight prison cluster[9] although treatment is excluded
from the pathway considered here. The study of the Isle of
BMC Public Health 2006, 6:170 http://www.biomedcentral.com/1471-2458/6/170
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Wight Prison Cluster considers prisoners as they first
attend a one hour health awareness lecture during which
they are alerted to the risk factors for blood-borne viruses
and are then invited to the healthwatch clinic which was
set up in 1997 to provide counselling on blood-borne
viruses for all new receptions to the Isle of Wight prisons.
Testing and counselling undertaken in the healthwatch
clinic on reception as described in the previous study[9]
are applied here and described below (Figure 2 and Figure
3). In addition verbal tests are introduced along the
screening pathway to investigate whether alternative HCV
case-finding strategies may be more cost effective than
offering testing to all individuals. Prisoners are given ver-
bal tests regarding their previous injecting behaviour and
results of previous HCV testing, with the answers to these
questions used to judge whether the prisoners are eligible
to receive serological HCV tests to establish their HCV sta-
tus.
The case-finding pathway is described in (Figure 2 and
Figure 3) and applies to all prisoners that are amongst the
proportion on reception that are covered by the HCV case-
finding programme (Figure 1). Initially all prisoners on
reception into prison attend a one hour health awareness
lecture alerting them to the risk factors of blood borne
viruses. During each lecture it is assumed that 10 prisoners
are present. Following this, prisoners are submitted to ver-
bal tests to determine their eligibility to receive antibody
tests. The verbal tests are a combination of the following,
and represent the alternative case-finding scenarios con-
sidered here:
1. Have you received a positive HCV test previously?
2. Have you ever injected illicit drugs?
The first question is asked to establish whether the pris-
oner has been previously diagnosed with HCV. This ques-
tion specifically asks about a previous positive test rather
than simply a previous test, as a previous negative test is
of no interest as it is likely that the prisoner may have been
exposed to HCV in the mean time. The 2nd question is
used to establish whether the person has ever injected
illicit drugs. Where verbal questioning is administered
(scenarios one to three, see below), the time taken to
question the prisoners is assumed to be independent of
the number of questions asked and is assumed to take 5
minutes, although this will be examined during sensitivity
analysis. Previous studies[10,16,17] have considered the
sensitivity and specificity of IDUs responses to questions
related to HCV positivity and the self-reporting of their
illicit behaviours. The values taken at baseline and applied
during sensitivity analysis are described in Table 2.
Following the verbal tests those prisoners that have been
identified as being eligible to receive serological testing
are assumed to be offered pre-test counselling. For those
prisoners that are willing to accept serological testing an
enzyme linked immunosorbant assay (ELISA) antibody
test is assumed to be administered. Prisoners identified as
having a positive antibody test are assumed to be
informed that they have evidence of contact with HCV
and are then offered a polymerase chain amplification
(PCR) test for the presence of HCV viral RNA as a marker
of ongoing infection. Those who are positive for HCV by
antibody testing but negative on a single PCR test are
assumed to be offered two further PCR tests as was
adopted in the Isle of Wight Study[9], the costs of which
are incorporated in the analysis.
Post-test counselling is administered to all prisoners on
receipt of the results from the ELISA and PCR tests. Those
with positive tests are assumed to be counselled on harm
reduction and harm minimisation. Assumed time and
staff allocations for each task on the case-finding pathway
are shown in Table 2, where no reference was available to
inform these values, reasonable assumptions were made
with the impact of these being examined during sensitiv-
ity analysis.
Community HCV testing and diagnosis
As a result of injecting treatment and prevention services
in the community, it is possible for some HCV positive
IDUs to become aware of their positive status as a result of
testing in the community. Further to this, HCV positive
individuals that develop symptoms associated with their
infection may also have their HCV infection diagnosed in
the community.
Assumed proportion of prison receptions covered by HCV case-fin ingFig re 1
Assumed proportion of prison receptions covered by HCV 
case-finding.
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Data was considered from the Unlinked Anonymous sur-
vey 2003–2004 of IDUs (who injected in the previous
four weeks prior to the survey) reporting whether they had
ever received a blood test for HCV by career length.
Assuming that this data is representative of the IDU pop-
ulation in the community and that no HCV testing had
been undertaken in prison, a model was fitted to the data
using maximum likelihood (fit not shown). The rate that
IDUs in the community are tested and diagnosed for HCV
in the community was estimated to be 0.15/IDU/year.
Case-finding scenarios
Varying the verbal questions asked on prison reception
allows us to compare six alternative case-finding scenarios
used to identify individuals that are eligible to receive an
offer of serological testing for HCV (the ELISA and PCR
tests offered being the same for scenarios one-four, see
above). A negative answer to any of the questions asked
indicates that the person is ineligible for HCV serological
testing. The verbal screening that distinguishes each sce-
nario is described in Table 1:
Pathway describing the administering of hepatitis C serological testsFigure 3
Pathway describing the administering of hepatitis C serological tests.
Schematic diagram of the case-finding scenarios used in this analysisFigure 2
Schematic diagram of the case-finding scenarios used in this analysis.
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Comparisons are made between each case-finding sce-
nario by considering the cumulative cost per chronic HCV
case (RNA positive) detected and how this varies over
time. The complete parameter set describing the case-find-
ing scenarios at baseline are shown in Table 2. The impli-
cation of these parameter selections on the model results
are examined during sensitivity analysis with the values
taken during sensitivity analysis also shown in Table 2. All
costs are presented in year 2004 with discounting rates for
both costs and benefits taken at 3.5% as recommended by
the HM Treasury[18] although the impact of these are var-
ied during sensitivity analysis (Table 2). The analysis here
is considered from the perspective of the health care pro-
vider.
Results
It can be seen (Figure 4. c) that scenario one: identifying
those individuals that have not received a past positive
HCV test, and have ever injected illicit drugs is the most
cost effective scenario over time. This shows the impor-
tance of identifying those individuals with a history of
injecting drug use, which is the biggest risk factor for HCV
Taking parameter values as baseline values (Table 2), the results for the first four case-finding scenarios compared with the cur-rent do nothing (no HCV case-finding in prisons) strategyFigure 4
Taking parameter values as baseline values (Table 2), the results for the first four case-finding scenarios compared with the cur-
rent do nothing (no HCV case-finding in prisons) strategy: a) the undiscounted annual cost of implementing each case-finding 
scenario, b) the undiscounted annual number of new HCV cases identified when implementing each case-finding scenario, c) 
the cumulative average cost per new HCV case detected with discounting, d) the proportion of those RNA positive that are 
identified over time.
Table 1: Summary of case-finding scenarios
Scenario Description
One Verbally screen for ever having received a past positive HCV test, and for ever having injected illicit drugs.
Two Verbally screen for a past positive HCV test only.
Three Verbally screening for ever injecting illicit drugs only
Four No verbal screening
Five No verbal screening and no testing (do nothing scenario)
BMC Public Health 2006, 6:170 http://www.biomedcentral.com/1471-2458/6/170
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Table 2: Model parameters and values used during sensitivity analysis
Parameter Baseline value Sensitivity Source (where available)
λ0 = force of infection for new initiates 0.1608 0.1314–0.1942 [13]
λ1 = force of infection for experienced IDUs 0.0526 0.0310–0.0863 [13]
Cost of Doctor £3.49/min 
(£209.40/hr)
GP:/home visit/min With Qualification costs 
With direct care staff costs[23]
Cost of Nurse £54/hour District Nurse (midpoint grade G)/hr with 
patient + extra costs[23]
Time Taken for BBV lecture/prisoner 10 patients/hr 1 patient/hr – 20 
patients/hr
[9]
% Nurse time 50% 0–100%
% Doctor time 50% 0–100%
Time taken to verbal test on reception into prison 5 min 1–15 min [24]
% Nurse time 50% 0–100% [24]
% Doctor time 50% 0–100% [24]
% Known HCV positive and say so 55% (midpoint) 23%–83% 23%[10], 83%[16],
% never received a positive HCV test but say they are HCV 
positive
1% 0%–10%
% IDUs that report IDU use (current or ever) 75% 30–90% Darke[17] reports that IDUs give reasonably 
reliable answers to questions about drug use.
% non-IDUs that report IDU use (current or ever) 0% 0–20%
Time Taken to Counsel prior to an ELISA test 25 min 10–60 min 25 min[3] 10–60 min[24]
% Nurse time 50% 0–100% [24]
% Doctor time 50% 0–100% [24]
Time taken to Administer ELISA test 5 min 1–10 min
% Nurse time 50% 0–100%
% Doctor time 50% 0–100%
Cost of ELISA test £12 £5–20 Virus reference department, HPA, Colindale 
(2005)
% of those offered who accept ELISA testing 85% 10–100% [24]
ELISA Sensitivity 97% 90–100% [24]
ELISA Specificity 99% 90–100% [24]
Time taken to administer PCR test 5 min 1–10 min
% Nurse Time 50% 0–100%
% Doctor Time 50% 0–100%
% of those offered who accept PCR testing 100% 50% Assuming that those that accept an ELISA 
test will then accept a PCR
PCR Sensitivity 100% 99%–100% [24]
PCR specificity 100% 99–100% [24]
Cost of PCR test £57 £50–80 Virus reference department, HPA, Colindale 
(2005)
Time taken to counsel the result of negative ELISA or PCR test 5 min 5–15 min
% Nurse time 50% 0–100%
% Doctor time 50% 0–100%
Time taken to counsel the result of a positive ELISA test 25 min 15–75 min [24] 15–75 min[24]
% Nurse time 50% 0–100%
% Doctor time 50% 0–100%
Time taken to counsel the result of a positive PCR test 25 min 15–75 min [24] 15–75 min[24]
% Nurse time 50% 0–100%
% Doctor time 50% 0–100%
Proportion infected with HCV that become HCV RNA 
positive
80% 54%–86% [2,25,26]
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infection. Least cost effective is scenario two: only identi-
fying those individuals that have not received a past posi-
tive HCV test. For all scenarios the cost per new HCV case
detected rises over time indicating that they become less
cost effective as time passes. This is due to IDUs returning
to prison that are already aware of their HCV infection,
leaving a smaller proportion of individuals on reception
into prison that have undiagnosed infection.
The undiscounted cost of implementing each case-finding
scenario is shown in (Figure 4a) . For each case-finding
scenario the cost increases up to a plateau in 2010 and
then is broadly constant from then on. The initial increase
and then plateau can be explained by the assumed
expanding coverage of HCV case-finding on prison recep-
tion over time up to a constant coverage from 2010
onwards. It can be seen that scenarios two and four are far
more costly than the remaining scenarios, however nei-
ther of these scenarios screens prisoners on prison recep-
tion for any previous injecting drug use, and as a
consequence many more ELISA and PCR tests are admin-
istered for scenarios two and four than are necessary. A
slight reduction in the cost was observed in scenarios one
and two from 2010 onwards, this is due to persons having
been diagnosed with HCV infection returning to prison
and then being verbally screened for a past positive HCV
test, hence reducing the costs further along each of the
case-finding pathways.
From Figure 4d it can be seen that scenarios two and four
identify the greatest proportion of individuals that are
RNA positive over time, however these scenarios are not
very cost effective due to the high costs required to admin-
ister them.
Results from the incremental analysis are reported in
Table 3, where the alternative strategies have been ranked
according to their cumulative discounted cost in 2017 and
the incremental cost-effectiveness ratios have been calcu-
lated. This highlights that scenario two is the most cost-
effective option and has the smallest budget impact (least
cost).
Sensitivity analysis
Figure 5 shows the impact of one-way sensitivity analysis
on the cumulative average cost per case detected in 2017
for case-finding scenario one compared with the current
do nothing policy. In each case only those parameters that
impact on the baseline value by greater than 10% are
shown. It can be seen that in many cases the parameter
values have little impact on the cost effectiveness of this
scenario and in all cases this scenario was found to be the
most cost-effective.
The parameters that have the largest impact on cost-effec-
tiveness were found to be the number of prisoners that
attend the blood-borne virus lecture on reception into
prison, and the proportion of prisoners that accept an
ELISA test. Also noted is the impact of non-IDUs (persons
that have never injected drugs) reporting previous inject-
ing drug use, however the authors could find no evidence
of this occurring during previous screening programmes.
It can be seen that the rate of HCV testing and diagnosis
in the community and the force of infection estimates in
the experienced IDUs also have an impact on the cost
effectiveness estimates of scenario one. An increase in the
rate of testing and diagnosis in the community and a
reduction in the force of infection in experienced IDUs
both result in the prison case-finding programme becom-
ing less cost effective.
Discussion
Using a Markov decision analysis model and a model of
the flow of IDUs through prison the work here estimates
the cost effectiveness of a number of alternative case-find-
ing strategies including verbal screening for ever injecting
drug use and for previous HCV testing. Results indicate
that verbally screening for ever injecting illicit drugs and
for ever having received a past positive HCV test was the
most cost effective approach to establishing prisoners eli-
Table 3: Incremental cost effectiveness analysis of each case-finding scenario
Case-finding Scenario Cumulative discounted cost in 2017 
(1,000s)
Cumulative discounted no. of cases of 
HCV identified in 2017
Incremental Cost Effectiveness
Five (Do Nothing) £0 0
One £28,192 13413 £2,102
Three £30,444 13548 £16,625
Four £53,123 17098 £6,388
Two £54,670 16927 dominated
Rate of HCV testing and diagnosis in the community 0.15 0.1–0.3 See text
Discount rate for costs 3.5% 0%–6% HM Treasury[18]
Discount rate for benefits 3.5% 0%–6% HM Treasury[18]
Table 2: Model parameters and values used during sensitivity analysis (Continued)
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The impact on the cumulative average cost effectiveness of scenario one in 2017 compared to the current no case-finding strategy when applying one-way sensitivity analysisFigure 5
The impact on the cumulative average cost effectiveness of scenario one in 2017 compared to the current no case-finding 
strategy when applying one-way sensitivity analysis. The bars represent the costs when the upper and lower parameter esti-
mates are implemented while the line through each is the baseline value.
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gible for serological testing, while sensitivity analysis
found that the proportion of eligible prisoners that accept
ELISA testing had a significant impact on the cost-effec-
tiveness of the case-finding scenarios.
It has been found that the case-finding scenarios
described here all become less cost-effective over time,
this being due to the impact of previously screened indi-
viduals returning to prison that do not need re-screening
and the time taken to identify these prisoners. Although a
reduction in annual costs were noted over time in some of
the case-finding scenarios due to prisoners that had
already received a positive serological test being identified
on prison reception. For each scenario when the propor-
tion of prison receptions covered by HCV case-finding
had been assumed to have reached a constant the costs
and benefits over time display only relatively small varia-
tion.
It is possible for an individual to become HCV RNA posi-
tive during a spell of imprisonment. This may occur for
two reasons; either the individual was infected while in
prison or the individual was infected outside prison but
due to the natural history of HCV, HCV RNA was not
detectable on reception into prison. HCV RNA can be
detected within 1 to 2 weeks after exposure to the virus
although HCV RNA positivity may appear much later at
30 to 40 days[19,20]. As two further PCR tests are admin-
istered to those individuals that are anti-HCV positive but
negative for HCV RNA it is unlikely that individuals
infected just prior to reception will remain undetected. If
however it is felt that there is a significant risk of some
prisoners becoming HCV RNA positive while in prison,
then to allow these individuals to be offered treatment or
counselling it may be necessary to administer some HCV
testing during an individuals prison sentence or perhaps
on discharge from prison.
The work has not given any consideration to the subject of
treatment although it is acknowledged that the inclusion
of the costs and benefits associated with treating individ-
uals that have been identified with HCV in prison will
play an important role in judging whether to implement
an HCV case-finding programme on reception into
prison. This study examines the best approach to identify-
ing individuals that may be eligible for treatment and this
can be taken forward when considering the implementa-
tion of treatment.
Results from sensitivity analysis showed the importance
of encouraging eligible prisoners to accept the offer of an
ELISA test, with a reduction in uptake having a large
impact on cost-effectiveness. Intervention measures out-
side prison such as testing and diagnosis in the commu-
nity or those that target IDUs aimed at reducing their at
risk behaviour (and therefore the FOI) can have a negative
impact on the cost-effectiveness of a prison based case-
finding programme even though a prison based pro-
gramme may well be more cost-effective than a pro-
gramme based in the community. This shows the
importance of coordinating intervention measures inside
and outside prison to ensure the maximum effectiveness
of both.
The work here has focused on identifying those individu-
als that may be at risk from HCV infection and then offer-
ing them an HCV test as appropriate, however it is
possible that an individual may encounter further prob-
lems if they admit to injecting drug use, this in many
instances may take the form of the social stigma associ-
ated with injecting drug use. It is hoped that admitting to
previous injecting drug use will be seen in a positive light
as individuals can then be targeted for drug related inter-
vention measures or HCV treatment if necessary. To allow
for the possibility that individuals may not give reliable
answers to questions regarding injecting drug use or HCV
status a range of values describing the sensitivity and spe-
cificity to individuals answers related to previous HCV
testing and injecting drug use were considered. It was
found that of importance to model results were the
answers that individuals gave to the issue of previous
injecting behaviour. However it is hoped that the one
hour health awareness lecture described at the start of the
screening pathway will provide a good opportunity in
which to address individuals concerns regarding the
revealing of potentially sensitive information.
A further account of screening for HCV in the prison pop-
ulation in England and Wales is described in a previous
study considering the experience of screening in the Dart-
moor prison[21]. In this study the authors describe data
collected from a cohort of prisoners screened from 1 Jan-
uary 1998 to 30 June 2001 describing progress from test
result to treatment. A key difference between the screening
pathway described in Dartmoor compared to the Isle of
Wight appears to be the additional two PCR tests admin-
istered at the Isle of Wight for those individuals that test
anti-HCV positive but HCV RNA negative after a first PCR
test. This means that the costs of the scenarios reported
here may be less cost-effective than if the requirement to
implement these two additional PCR tests was removed.
The approach to staff costs in this work has considered
only the role of a doctor and nurse in implementing the
alternative case-finding scenarios, while the estimates of
the length of time taken to undertake the individual tasks
along the case-finding pathways are inevitably subject to
much variation. Considering only doctors and nurses is
an obvious over simplification, with other members of
staff such as prison chaplains and guards playing a role in
BMC Public Health 2006, 6:170 http://www.biomedcentral.com/1471-2458/6/170
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the implementation of a prison based case-finding pro-
gramme, However in mitigation the results from the sen-
sitivity analysis have shown that staff costs and length of
time required to accomplish each task play only a small
part in variation in the estimates of the cost-effectiveness
of the case-finding scenarios.
While treatment has not been considered here, there are
still advantages in identifying those individuals that are
anti-HCV positive. Any individual that is anti-HCV posi-
tive obviously has the potential to transmit infection par-
ticularly if the person is an IDU and continues to inject
illicit drugs. An awareness of the infected status of these
individuals is useful to services as they can then be tar-
geted for intervention measures aimed at reducing the
behaviour that leads to further HCV transmission. This
may take the form of encouraging injecting cessation or
the supplying of clean needles to reduce the risk of trans-
mission due to the sharing of syringes. A further advan-
tage of case-finding is that HCV positive individuals can
be monitored so that they can be treated when treatment
criteria have been met, which in the case of IDUs will be
when the individual has ended their injecting career[22].
Finally the identification of HCV positive individuals on
prison reception may also assist in identifying further pos-
itive individuals in the community through contact trac-
ing exercises.
Future work should consider the cost-effectiveness of HCV
treatment in a prison setting, including the possibility that
some individuals may require a treatment pathway that
involves continued treatment in the community follow-
ing discharge from prison. The model here has not consid-
ered infection in the non-IDU population, and has
assumed that all infection is as a result of injecting illicit
drugs. While it is acknowledged that there is some HCV
infection in the non-IDU population this is likely to be
insignificant compared to injection related infection[4].
However it would be beneficial if FOI estimates could be
obtained that consider the possibility of HCV infection
due to risk factors not associated with injecting drug use,
and the possibility of increased risk of infection in a
prison setting. The model here could then be re-parame-
terised to reflect this new information.
Conclusion
It has been shown here that verbally screening for ever
injecting illicit drugs and for ever having received a past
positive HCV test is the most cost effective approach to
establishing prisoners eligible for HCV serological testing.
The results from sensitivity analysis show the importance
of encouraging eligible prisoners to accept ELISA testing
with this having a significant impact on the cost-effective-
ness of the case-finding scenarios.
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